

Synthetic Notch receptor

SynNotch receptors can be engineered to sense a tumor antigen and induce the expression of a CAR to a second tumor-related antigen.

Zhang et al. presented recent preclinical and clinical studies targeting well-characterized glioblastoma antigens, which include the IL13RA2 and the epidermal growth factor receptor. Afterward, they turn their attention to alternative targets in glioblastoma, including less-explored antigens such as B7-H3 (CD276), carbonic anhydrase 9, and the GD2 ganglioside. They also discuss additional target ligands, namely CD70, and NKG2D. Finally, they present the possibilities afforded by novel CAR architectures. In particular, they examine the use of armored CARs to improve the survival and proliferation of CAR T cells. They conclude by discussing the advantages of tandem and synNotch CARs when targeting multiple glioblastoma antigens ¹⁾.

¹⁾

Zhang J, Siller-Farfán JA. Current and future perspectives of chimeric antigen receptors against glioblastoma. Immunother Adv. 2022 Jun 1;2(1):ltac014. doi: 10.1093/immadv/ltac014. PMID: 36284838; PMCID: PMC9585667.

From:

<https://neurosurgerywiki.com/wiki/> - Neurosurgery Wiki

Permanent link:

https://neurosurgerywiki.com/wiki/doku.php?id=synthetic_notch_receptor

Last update: 2024/06/07 02:57

